StockNews.com assumed coverage on shares of MEI Pharma (NASDAQ:MEIP – Free Report) in a research note issued to investors on Sunday morning. The brokerage issued a buy rating on the stock.
MEI Pharma Stock Performance
NASDAQ MEIP opened at $2.87 on Friday. The stock has a fifty day moving average of $2.68 and a 200-day moving average of $2.93. The stock has a market capitalization of $19.11 million, a P/E ratio of -0.41 and a beta of 0.78. MEI Pharma has a 52 week low of $2.30 and a 52 week high of $4.97.
MEI Pharma (NASDAQ:MEIP – Get Free Report) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($1.20) EPS for the quarter. Equities research analysts forecast that MEI Pharma will post -5.1 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
MEI Pharma Company Profile
MEI Pharma, Inc, a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor for the treatment of patients with relapsed/refractory follicular lymphoma; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase I clinical trial for acute myeloid leukemia and B-cell malignancies.
See Also
- Five stocks we like better than MEI Pharma
- The Role Economic Reports Play in a Successful Investment Strategy
- Survey Reveals: Top 150 Best Coffee Shops for Remote Workers and Business Deals [2025]
- Insider Trades May Not Tell You What You Think
- What Does the Future Hold for Eli Lilly?
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- Oracle Stock Drops Nearly 14% – Is Now the Time to Buy?
Receive News & Ratings for MEI Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEI Pharma and related companies with MarketBeat.com's FREE daily email newsletter.